A New Approach to the Prophylaxis of Cyclic Vomiting: Topiramate

Abstract

BACKGROUND/AIMS: The aim of this study was to compare the efficacy and tolerability of topiramate and propranolol in preventing pediatric cyclic vomiting syndrome. METHODS: A retrospective medical-record review of patients who underwent prophylaxis after receiving a diagnosis of cyclic vomiting syndrome was performed. Patients who completed at least 12 months of treatment were included in the analysis. Responder rate, and adverseevent rates were also calculated from all patients. Response to treatment was assessed as the total number of vomiting attacks per year. Patients in whom the frequency of vomiting attack reduced greater or equal to 50% were defined as responders, and the remaining patients were classified as nonresponders. RESULTS: = 0.240). CONCLUSIONS: The efficacy of topiramate was superior to propranolol for the prophylaxis of pediatric cyclic vomiting syndrome.